Vaso Active Pharmaceuticals, Inc. (Vaso Active), incorporated in January 2003, is an early-stage company focused on commercializing, marketing and selling over-the-counter (OTC) pharmaceutical products that incorporate its PENtoCORE technology. The Company is also focused on pre-clinical testing and research on a vaso active lipid encapsulated (VALE) technology. The technology uses an active process incorporating chemical vasodilators to deliver drugs through the skin and into the bloodstream. The PENtoCORE technology is a topical formulation, in contrast to the VALE transdermal technology. The Company is marketing three products based on the PENtoCORE technology: Osteon, an OTC external analgesic; A-R Extreme, an OTC external analgesic, and Termin8, an OTC antifungal lotion. The Company markets three products: Osteon, which is designed to provide temporary relief from muscular-skeletal pain associated with arthritis; A-R Extreme, which is designed to provide temporary relief from muscle and joint pain associated with athletic activity; and Termin8, which is designed to treat athlete's foot. Vaso Active has a product candidate, RepiDerm, for the treatment of acne. The formulation of the product has been completed and the Company is working on labeling, package design and branding for the product. Vaso Active has five additional product candidates at various stages of formulation and development. Vaso Active has identified six additional OTC product candidates that will utilize either the VALE transdermal or PENtoCORE topical technology. Each of these product candidates is in various stages of development for the Company by BioChemics and they are not yet available for sale. Vaso Active has finalized a formulation of its acne treatment candidate utilizing its PENtoCORE topical technology. The product would contain 10% benzoyl peroxide (BPO) as an active ingredient. The Company is in the preclinical phase of development for its ibuprofen product candidate. Vaso Active has a number of formulas under development for it by BioChemics for OTC drug monograph product candidates. None of the formulas have been finalized. The Company is in the formulation development stage of its toenail fungus product candidate. In February 2003, Vaso Active entered into a development and manufacturing agreement with BioChemics, Inc. with respect to the ongoing manufacturing and development of its products and product candidates. Under this agreement, BioChemics will research, develop and manufacture products for the Company pursuant to specific purchase orders submitted by it from time to time. BioChemics does not manufacture Vaso Active's products itself, but rather uses two different privately owned third party companies as its contract manufacturers. Until August 2005, BioChemics was engaged in developing a transdermal ibuprofen product on the Company's behalf. In August 2005, Vaso Active instructed BioChemics to cease further development of the ibuprofen product candidate on its behalf. On July 20, 2005, the Company entered into a brokerage agreement with Ferolie Corporation, doing business as Eastern Sales & Marketing (ESM) to sell all of its products across all classes of retail trade in the continental United States. ESM is a full-service sales, marketing and merchandising agency that provides services for consumer packaged goods manufacturers in various product categories, including food, drug, specialty and private label. In addition, under the agreement, ESM will be Vaso Active's agent to identify prospective licensees of its trademarks and trade names.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for VAPH